Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLC

J Thorac Oncol. 2019 Oct;14(10):e215-e216. doi: 10.1016/j.jtho.2019.07.001. Epub 2019 Jul 11.

Authors

Jose Carlos Benitez¹, Laura Mezquita², Rapahël Colle², Lambros Tselikas³, Angela Botticella⁴, Caroline Caramella³, Benjamin Besse⁵

Affiliations

¹ Medical Oncology Department, Hospital Universitari Mutua Terrassa, Barcelona, Spain.
² Cancer Medicine Department, Gustave Roussy, Villejuif, France.
³ Radiology Department, Gustave Roussy, Villejuif, France.
⁴ Radiotherapy Department, Gustave Roussy, Villejuif, France.
⁵ Cancer Medicine Department, Gustave Roussy, Villejuif, France; Paris-Sud University, Orsay, France. Electronic address: benjamin.besse@gustaveroussy.fr.

PMID: 31302233
DOI: 10.1016/j.jtho.2019.07.001

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / secondary
Adenocarcinoma of Lung / therapy
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / secondary
Carcinoma, Non-Small-Cell Lung / therapy
Combined Modality Therapy
Female
Fluorouracil / administration & dosage
Hepatic Artery*
Humans
Immunotherapy / methods*
Infusions, Intravenous
Leucovorin / administration & dosage
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Lung Neoplasms / therapy
Middle Aged
Nivolumab / administration & dosage
Oxaliplatin / administration & dosage
Prognosis
Radiosurgery

Substances

Oxaliplatin
Nivolumab
Leucovorin
Fluorouracil